Follow the Money: Fate Therapeutics, Inc.
Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.
Fate Therapeutics, Inc. is a U.S. public pharmaceutical company that develops therapeutics based on modulating cell fate. As reported in the May 28, 2015 issue of the PharmSource Lead Sheet, Fate raised $32 million in the completion of a secondary public offering.
- Fate Therapeutics was incorporated in Delaware in 2007.
- Corporate Headquarters: San Diego, CA – approximately 23,684 square feet of office and laboratory space.
- As of December 31, 2014, Fate had 50 employees, including 23 engaged in R&D and 17 in clinical development and regulatory affairs.
- Fate plans to use the proceeds to support clinical R&D activities, working capital and other general corporate purposes.
- The company relies on third parties to support the conduct of clinical trials and preclinical studies.
- Fate does not own or operate manufacturing facilities and relies on contract manufacturers for all required materials for clinical trials.
- The company has no sales, marketing or distribution capabilities.
- On May 4, 2015, Fate Therapeutics entered into a collaboration with Juno Therapeutics. Fate will study small molecules in an effort to boost Juno’s genetically-engineered T cell product candidates and turbocharge their effectiveness against cancer. Juno will pay Fate $5 million upfront and purchase one million shares of Fate common stock at $8 per share, as well as fund all mutual collaboration activities for an exclusive four-year research term.
|Product Candidate||Indication||Dosage Form||Status||Next Anticipated Step|
|iPSC-derived CD34+, NK & T cells||Not disclosed||Parenteral||Preclinical||TBA|
|iPSC-derived myogenic cells||Muscle Regeneration||Parenteral||Preclinical||TBA|
|PD-L1 Programmed CD34+ cells||Autoimmune disorders||Parenteral||Preclinical||TBA|
|Programmed CAR-T/TCR||Adoptive immunotherapies||Parenteral||Preclinical||TBA|
|Programmed HCs||Not disclosed||Parenteral||Preclinical||TBA|
|ProTmune||Hematologic malignancies (adult)||Parenteral||Preclinical||Plans to submit IND in 2015|
|ProHema||Inherited metabolic disorders (pediatric)||Parenteral – Liquid||Phase Ib||TBA|
|ProHema||Hematologic malignancies (pediatric)||Parenteral – Liquid||Phase Ib||TBA|
|ProHema||Hematologic malignancies (adult)||Parenteral – Liquid||Phase II||TBA|
|(In $ thousands)||2014||2013|
|General & Administrative Expenditures|
|Total Operating Expenses|
|Fate Therapeutics, Inc.||Key Officers|
|3535 General Atomics Court, Suite 200||Christian Weyer, MD, President & CEO|
|San Diego, CA 92121, USA||Dan Shoemaker, PhD, CSO|
|Phone: 858-875-1800||Wendy Levi MD, VP, Clinical Development|
|Web: www.fatetherapeutics.com||John Ferraro, VP, Clinical Operations|
|Moya Daniels, VP, Regulatory Affairs, CMC & Quality Assurance|